Gilgamesh Pharmaceuticals Awarded $14 Million National Institute on Drug Abuse Grant to Advance Novel, Cardiac-Safe Ibogaine Analog for the Treatment of Opioid Use Disorder

Grant to support IND-enabling toxicology and Phase 1/1b development of novel cardiac-safe ibogaine analog, GM-3009 NEW YORK, March 14, 2024 /PRNewswire/ — Gilgamesh Pharmaceuticals, a clinical-stage neuroscience company committed to developing best-in-class, rapid-acting treatments for…